BHVN Biohaven Ltd.
USHealthcareAs of 2026-07-10 16:00
Why BHVN matters now
Biohaven Ltd. (BHVN) is a US stock in Healthcare. The latest InvestLog snapshot shows $15.55 with -7.39% on the session and $1.65B in market capitalization; recent performance reads 1-month +61.74% and YTD +20.19%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-130.5M, and EPS of $-0.88. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -41.4%.
The latest indexable market news headline is "Biohaven Announces Scientific Leadership Transitions" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $18.00; recent insider activity includes GREGORY JULIA P filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
15.47
P/S
0.00
EV/EBITDA
-2.27
DCF Value
$-0.60
FCF Yield
-41.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-866.5%
ROA
-138.9%
ROIC
-155.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-130.5M | $-0.88 |
| Q4 2025 | $0.00 | $-145.6M | $-1.21 |
| FY 2025 | $0.00 | $-738.8M | $-6.86 |
| Q3 2025 | $0.00 | $-173.4M | $-1.64 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$17.60
Target (Median)
$18.00
Target Range
$10.00 - $23.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
3.31
Biohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions.